Published in Transl Psychiatry on January 05, 2016
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Schizophrenia and increased risks of cardiovascular disease. Am Heart J (2005) 4.90
Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry (2002) 4.03
The environment and schizophrenia. Nature (2010) 3.86
Neurobiology of schizophrenia. Neuron (2006) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry (2011) 3.33
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2007) 3.22
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci (2011) 2.82
Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev (2007) 2.58
The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry (2012) 2.34
Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry (2001) 2.23
The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res (2015) 2.14
High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. Circulation (2009) 2.08
Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr Scand (2008) 2.07
An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci (1997) 2.03
S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes (2005) 1.91
Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry (2007) 1.89
Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry (2013) 1.87
Haemostatic changes in pregnancy. Thromb Res (2004) 1.83
Microglial phagocytosis of live neurons. Nat Rev Neurosci (2014) 1.79
PAI-1 and atherothrombosis. J Thromb Haemost (2005) 1.71
Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol (1990) 1.64
The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci (2011) 1.54
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr Res (2009) 1.48
Exercise therapy for schizophrenia. Cochrane Database Syst Rev (2010) 1.45
Crosstalk between inflammation and thrombosis. Maturitas (2004) 1.44
Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood (1985) 1.33
Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation (2005) 1.32
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol (2002) 1.30
Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood (2003) 1.26
Neurotrophins and schizophrenia. Schizophr Res (2007) 1.24
Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci (2000) 1.18
Remodelling at the maternal-fetal interface: relevance to human pregnancy disorders. Reproduction (2010) 1.16
Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull (2012) 1.14
Molecular basis of protein S deficiency. Thromb Haemost (2007) 1.14
Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature. Nutr Metab (Lond) (2009) 1.13
Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry Clin Neurosci (2008) 1.12
TAM receptors support neural stem cell survival, proliferation and neuronal differentiation. PLoS One (2014) 0.99
Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci (2012) 0.97
Atherosclerosis as inflammation. Ann Vasc Surg (2005) 0.94
Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res (2002) 0.94
Protein S confers neuronal protection during ischemic/hypoxic injury in mice. Circulation (2003) 0.93
Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci (2010) 0.93
An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes. J Hum Genet (2010) 0.93
Electroconvulsive seizure, but not imipramine, rapidly up-regulates pro-BDNF and t-PA, leading to mature BDNF production, in the rat hippocampus. Int J Neuropsychopharmacol (2012) 0.92
The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study. Compr Psychiatry (2012) 0.92
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci (2014) 0.92
Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration. J Neural Transm (Vienna) (2004) 0.91
Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res (2013) 0.90
Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep (2010) 0.87
Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues. Neurosci Lett (2001) 0.87
Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin. Biochem J (2007) 0.87
Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells. Biochem Biophys Res Commun (2010) 0.86
Increased cortical neuronal density in schizophrenia. Am J Psychiatry (2004) 0.85
Protease-activated receptor-1 modulates hippocampal memory formation and synaptic plasticity. J Neurochem (2012) 0.85
Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. Arch Gynecol Obstet (2010) 0.84
Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease. Neurosci Lett (1993) 0.83
Subacute intranasal administration of tissue plasminogen activator promotes neuroplasticity and improves functional recovery following traumatic brain injury in rats. PLoS One (2014) 0.83
Serine proteases, serine protease inhibitors, and protease-activated receptors: roles in synaptic function and behavior. Brain Res (2011) 0.82
Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. Schizophr Res (2014) 0.82
Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) all-day satellite, Scottsdale, Arizona. The rapporteurs' report. Schizophr Res (2009) 0.82
Positive association of phencyclidine-responsive genes, PDE4A and PLAT, with schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2011) 0.81
From plasminogen to plasmin: role of plasminogen receptors in human cancer. Int J Mol Sci (2014) 0.80
Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke. Stroke (2014) 0.80
Involvement of tissue plasminogen activator-plasmin system in depolarization-evoked dopamine release in the nucleus accumbens of mice. Mol Pharmacol (2006) 0.80
Extracellular proteolysis of reelin by tissue plasminogen activator following synaptic potentiation. Neuroscience (2014) 0.79
Neuropsychiatric findings in Cushing syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin North Am (2013) 0.79
Markers of low activity of tissue plasminogen activator/plasmin are prevalent in schizophrenia patients. Schizophr Res (2014) 0.79
Cancer in parents of persons with schizophrenia: is there a genetic protection? Schizophr Res (2012) 0.78
Multiple roles of tissue plasminogen activator in schizophrenia pathophysiology. Semin Thromb Hemost (2013) 0.78
Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics. Br J Haematol (2013) 0.78
Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment. Curr Pharm Des (2014) 0.78
Homocysteine: a sulph'rous fire. J Clin Invest (2001) 0.77
Vitamin K-dependent proteins: functions in blood coagulation and beyond. Thromb Haemost (2008) 0.77
Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses (2012) 0.77
Pivotal role of tissue plasminogen activator in the mechanism of action of electroconvulsive therapy. J Psychopharmacol (2013) 0.77
Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res (2015) 0.76
Activation of post-synaptic dopamine D₁ receptors promotes the release of tissue plasminogen activator in the nucleus accumbens via PKA signaling. J Neurochem (2007) 0.76
Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res (2009) 0.75
Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy. Schizophr Res (2015) 0.75